It can be inferred that, in the case of patients with well-preserved insulin secretory function, insulin secretion could be enhanced to compensate for increased insulin resistance when immunosuppressants are administered during the post-transplantation period, thereby preventing the exacerbation of glucose metabolism. This evidence concerns the gene INS and Insulin resistance.